Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.
Since our inception, our focus has been targeting novel innate immune pathways where the biology had not yet translated into innovative therapies. We have leveraged our expertise in innate immunity to discover and develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. One of Kineta’s key competitive advantages was building a strong foundation with an industry-leading scientific team who drive our research and development engine bolstered by an exceptional immuno-oncology focused scientific advisory board. We have integrated strong commercial leadership with our research and development team to enable Kineta to advance multiple drug programs in areas with high unmet needs and significant commercial potential.
“We aim to improve outcomes
for cancer patients
through our scientific innovation.”
Shawn Iadonato — Kineta CEO
Kineta is led by a team with diverse talents who are recognized for their expertise in drug development, corporate finance and success in bringing new pharmaceutical therapies to market.